Context Therapeutics Acquires Phase 1-ready T cell Engager CT-95
CT-95 is a potentially first-in-class mesothelin x CD3 bispecific antibody Acquisition expands Context pipeline with second clinical-stage T cell engager for solid tumors PHILADELPHIA, July 10, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced that it has entered into an asset purchase agreement under which the Company has acquired CT-95, formerly owned by Link Immunotherapeutics, Inc. ("Link"), a mesothelin ("MSLN") x CD3 T cell engaging ("TCE") bispecific antibody with first-in-class potential that has received Investigational New Drug ("IND") clearance from th
